Brief: Agenus Inc Reports Quarterly Loss Per Share Of $0.24
March 14 (Reuters) - Agenus Inc AGEN.O :
* AGENUS REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL
RESULTS AND OUTLINES 2023 OBJECTIVES
* AS OF DECEMBER 31, 2022, HAD CASH, CASH EQUIVALENT AND
SHORT-TERM INVESTMENT BALANCE OF $193 MILLION
* QTRLY LOSS PER SHARE $0.24
* CONFIRMATORY PHASE 3 TRIAL IN MSS CRC IS EXPECTED TO BE
LAUNCHED
IN 2023
* Q4 EARNINGS PER SHARE VIEW $-0.22 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX4b3nJF
Further company coverage: AGEN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Agenus
See all newsBrief: Agenus Reports 72% Of Patients With Locally Advanced Dmmr Colon Cancer Had No Cancer Remaining At Surgery Following Six Weeks Of Bot+Bal In Phase 2 Neoasis Study At Esmo 2026
Brief: Armenia Grants First Marketing Authorizations For Agenus’ Bot+Bal In Previously Treated Mss Metastatic Colorectal Cancer
Brief: Agenus - Unit Enters Second Loan Modification Agreement With Ocean 1181 On Aug 12, 2026 - SEC Filing
Agenus Inc reports results for the quarter ended June 30 - Earnings Summary
Agenus Q2 revenue rises on access and royalty income